Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06634940 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

International Surveillance of Antimicrobial Resistance in Cirrhosis-Related Infections

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Study First Submitted
What is this study about? This study tracks antibiotic resistance in patients with cirrhosis who develop bacterial infections. Cirrhosis is a condition where the liver is severely scarred, and people with cirrhosis are at high risk for serious bacterial infections. Why is this study important? Bacterial infections are common in patients with cirrhosis, affecting 25-46% of those who are hospitalized. These infections can be life-threatening, with 1 in 4 patients dying from complications. Many of these infections are becoming harder to treat because the bacteria are resistant to antibiotics. Infections caused by resistant bacteria are increasing, which makes finding the right antibiotic quickly even more difficult. In other regions of the world, guidelines exist to help doctors choose the right antibiotics for cirrhosis patients. However, in Latin America, we don't have specific guidelines for our region, and doctors currently rely on recommendations from the U.S. or Europe. These guidelines may not reflect the local patterns of bacterial infections and resistance we see here. What is the goal of this study? The main goal of this study is to create a long-term system to track how bacteria respond to antibiotics in patients with cirrhosis in Latin America. By collecting data from hospitals across different countries, we aim to: * Identify how many infections are caused by multidrug-resistant bacteria. * Understand how antibiotics (such as ceftriaxone, vancomycin, and carbapenems) act against these infections. * Generate reports informing bacterial resistance patterns to help doctors make better patient treatment decisions. What do we hope to achieve? We hope the data we collect will help develop guidelines for patients with cirrhosis in Latin America. These guidelines will ensure that doctors use the most effective antibiotics based on real-time data from our region. This should improve patient outcomes and help prevent the spread of resistant bacteria.
Trial Details
NCT Number NCT06634940
Lead Sponsor Hospital Italiano de Buenos Aires
Conditions
(from sponsor)
Cirrhosis, Bacterial Infections, Multidrug Resistance
Related terms Bacterial Infections, Fibrosis
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov